↓ Skip to main content

Refinement and revalidation of the demoralization scale: The DS‐II—external validity

Overview of attention for article published in Cancer (0008543X), May 2016
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (91st percentile)
  • Good Attention Score compared to outputs of the same age and source (76th percentile)

Mentioned by

news
1 news outlet
blogs
1 blog
twitter
13 X users

Citations

dimensions_citation
79 Dimensions

Readers on

mendeley
106 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Refinement and revalidation of the demoralization scale: The DS‐II—external validity
Published in
Cancer (0008543X), May 2016
DOI 10.1002/cncr.30012
Pubmed ID
Authors

Sophie Robinson, David W Kissane, Joanne Brooker, Courtney Hempton, Natasha Michael, Jane Fischer, Michael Franco, Merlina Sulistio, David M Clarke, Mehmet Ozmen, Susan Burney

Abstract

The recently refined Demoralization Scale-II (DS-II) is a 16-item, self-report measure of demoralization. Its 2 factors-Meaning and Purpose and Distress and Coping Ability-demonstrate sound internal validity, including item fit, unidimensionality, internal consistency, and test-retest reliability. The convergent and discriminant validity of the DS-II with various measures is reported here. Patients who had cancer or other progressive diseases and were receiving palliative care (n = 211) completed a battery of questionnaires, including the DS-II and measures of symptom burden, quality of life, depression, and attitudes toward the end of life. Spearman ρ correlations were determined to assess convergent validity. Mann-Whitney U tests with calculated effect sizes were used to examine discriminant validity and establish the minimal clinically important difference (MCID). Cross-tabulation frequencies with chi-square analyses were used to examine discriminant validity with major depression. The DS-II demonstrated convergent validity with measures of psychological distress, quality of life, and attitudes toward the end of life. It also demonstrated discriminant validity, as the DS-II differentiated patients who had different functional performance levels and high/low symptoms, with a difference of 2 points between groups on the DS-II considered clinically meaningful. Furthermore, discriminant validity was demonstrated, as comorbidity with depression was not observed at moderate levels of demoralization. The DS-II has sound psychometric properties and is an appropriate measure of demoralization. Given its structural simplicity and brevity, it is likely to be a useful tool in meaning-centered therapies. Cancer 2016. © 2016 American Cancer Society.

X Demographics

X Demographics

The data shown below were collected from the profiles of 13 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 106 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Malaysia 1 <1%
Unknown 105 99%

Demographic breakdown

Readers by professional status Count As %
Student > Master 16 15%
Student > Ph. D. Student 10 9%
Researcher 9 8%
Student > Doctoral Student 8 8%
Student > Bachelor 5 5%
Other 18 17%
Unknown 40 38%
Readers by discipline Count As %
Psychology 19 18%
Medicine and Dentistry 17 16%
Nursing and Health Professions 9 8%
Unspecified 4 4%
Agricultural and Biological Sciences 2 2%
Other 10 9%
Unknown 45 42%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 22. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 October 2020.
All research outputs
#1,732,465
of 25,394,764 outputs
Outputs from Cancer (0008543X)
#1,449
of 14,100 outputs
Outputs of similar age
#28,942
of 326,318 outputs
Outputs of similar age from Cancer (0008543X)
#37
of 160 outputs
Altmetric has tracked 25,394,764 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 93rd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 14,100 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 15.4. This one has done well, scoring higher than 89% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 326,318 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 91% of its contemporaries.
We're also able to compare this research output to 160 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 76% of its contemporaries.